GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that ten scientific abstracts highlighting ultra-low-field imaging will be presented at the Radiological Society of North America (RSNA) 2024 Annual Meeting in Chicago. For Hyperfine, this marks the largest number of presentations at RSNA to date, underscoring the growing interest in and expanding applications of the Swoop® system across varied professional healthcare environments.
“We’re excited by the scientific community’s remarkable enthusiasm for the Swoop® system,” said Dr. Edmond Knopp, Hyperfine Chief Medical Officer. “Watching our technology propel real-world applications across such diverse settings is a significant milestone for Hyperfine. We look forward to continued momentum with clinical evidence on the use of portable brain MRI and how it can transform brain imaging and enhance patient care.”
The ten abstracts highlight a broad range of clinical and technical applications across multiple sites of care, showcasing the Swoop® system’s versatility in supporting patient management. Clinical research to be presented spans workflow in both the emergency department and neuro ICU and covers clinician experience in intracerebral hemorrhage monitoring, acute ischemic stroke detection, and advanced imaging techniques for multiple sclerosis.
For more information about the Swoop® Portable MR Imaging® system, please visit hyperfine.io.
Conference attendees can learn more during the presentations listed below.
Name: Acute stroke detection using portable ultra low-field MRI: A multicenter outlook
Presented by: Nandor Kolos Pinter, MD
Session: Neuroradiology (Stroke: Diagnosis and Treatment) | M3-SSNR04
Date and time: Monday, December 2, 9:30–10:30 AM
Location: S406B
Name: Low-field (64mT) portable brain MRI in hospitalized and emergency department patients: Real-world experience from our first two years
Presented by: Vinu Mathew, MD
Session: Science Session (Low-Field and Mobile MRI) | T2-STCE1
Date and time: Tuesday, December 3, 9:00–9:30 AM
Location: Learning Center Theater 1
Name: Application of clinical low field mobile MRI in a large academic medical center
Presented by: Farzaneh Rahmani, MD, MPH
Session: Science Session (Low-Field and Mobile MRI) | R2-STCE1
Date and time: Thursday, December 5, 9:00–9:30 AM
Location: Learning Center Theater 1
Name: Utility of low-field portable brain MRI for ruling out space-occupying lesions and hydrocephalus in patients with papilledema and other ophthalmologic signs of possible increased intracranial pressure: Preliminary experience
Presented by: Timothy Reynold Uy Lim, MD
Session: Science Session (Low-Field and Mobile MRI) | M3-STCE2
Date and time: Monday, December 2, 10:00–10:30 AM
Location: Learning Center Theater 2
Name: Efficacy of follow-up portable MRI compared to standard follow-up head CT for interval evaluation of traumatic intracranial hemorrhage
Presented by: Lauren Thompson
Session: Science Session (Low-Field and Mobile MRI) | T6-STCE2
Date and time: Tuesday, December 3, 1:30–2:00 PM
Location: Learning Center Theater 2
Name: A deep learning framework for generating synthetic low-field imaging with paired high and low-field data
Presented by: Alfredo Lucas, MS, BS
Session: Science Session (Low-Field and Mobile MRI) | R2-STCE1
Date and time: Thursday, December 5, 9:00–9:30 AM
Location: Learning Center Theater 1
Name: Quantifying brain volumes and lesion burden in relation to disease duration and severity in multiple sclerosis with low-field MRI
Presented by: Alfredo Lucas, MS, BS
Session: Science Session (Low-Field and Mobile MRI) | S1-STCE1
Date and time: Sunday, December 1, 9:30–10:00 AM
Location: Learning Center Theater 1
Name: Detecting myelin loss at 0.064T using a novel myelin water imaging technique: A multiple sclerosis case study
Presented by: Shannon H. Kolind, PhD
Session: Science Session (Low-Field and Mobile MRI) | M7-STCE1
Date and time: Monday, December 2, 2:30–3:00 PM
Location: Learning Center Theater 1
Name: Implementation and reproducibility assessment of myelin-sensitive scans with mobile ultra-low field MRI
Presented by: Sharada Balaji
Session: Science Session (Low-Field and Mobile MRI) | R2-STCE1
Date and time: Thursday, December 5, 9:00–9:30 AM
Location: Learning Center Theater 1
Name: Initial experience with low-field point-of-care MRI in animal stroke models
Presented by: Nandor Kolos Pinter, MD
Session: Neuroradiology Wednesday Afternoon Poster Discussions I | W5A-SPNR
Date and time: Wednesday, December 4, 12:15–12:45 PM
Location: Learning Center (Poster Session)
About the Swoop® Portable MR Imaging® System
The Swoop® Portable MR Imaging® system is U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. It is a portable, ultra-low-field magnetic resonance imaging device for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. The Swoop® system also has CE certification in the European Union and UKCA certification in the United Kingdom. The Swoop® system is commercially available in a select number of international markets.
About Hyperfine, Inc.
Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit hyperfine.io.
The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the “Company”) may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s goals and commercial plans, the benefits of the Company’s products and services, and the Company’s future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company’s product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company’s business; the inability to maintain the listing of the Company’s Class A common stock on the Nasdaq; the Company’s inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services and reimbursement for medical procedures conducted using the Company’s products and services; the Company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties indicated from time to time in Company’s filings with the Securities and Exchange Commission, including those under “Risk Factors” therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
